Before the fourth biologic in PsA, look for what is not inflammation

Design

Multinational registry cohort from 5 Nordic biologics registries

Population

14,362 patients with PsA starting a first b/tsDMARD, 1999–2020

Primary outcome

Prevalence of difficult-to-manage and treatment-refractory PsA

Effect

≥2 discontinuations 36%; difficult-to-manage 2%; treatment-refractory 1.2%

Researchers pooled five Nordic biologics registries covering 14,362 people with psoriatic arthritis who started a biologic or targeted synthetic DMARD between 1999 and 2020, applying components inspired by the EULAR framework for difficult-to-manage and treatment-refractory disease.

Over a median 6.3 years, 36% stopped at least two advanced therapies, 18% at least three and 10% at least four. Yet once persistent symptoms and objective disease activity were required, only 2–3% were difficult to manage, and about 1.2% were treatment-refractory with ongoing objective inflammation. Female sex, depression and opioid use became more frequent with each additional discontinuation.

The registry design could not test the EULAR definitions formally. But the gap between how often drugs are stopped and how rarely objective inflammation persists is striking.

The practical change is to look for non-inflammatory drivers, such as fibromyalgia, depression, opioid-related pain and mechanical problems, before cycling to yet another mechanism of action.

• Check for objective inflammation (joint counts, CRP, imaging) before switching another biologic.
• Screen for depression and fibromyalgia in patients cycling through therapies.
• Review opioid use as a contributor to persistent pain.
• Consider mechanical or degenerative causes of ongoing joint pain.

Why it matters

Most apparent biologic failure in PsA was not ongoing inflammation, so another switch may not help.

Don't overread it

Registry-based components approximated the EULAR definitions; they were not validated against them.

The statistics, in plain English

The contrast between 36% stopping two or more drugs and about 1.2% meeting a refractory definition means most discontinuations were not explained by drug inefficacy with ongoing objective inflammation. Patients stopped for side effects, other reasons, or without objective disease.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.